A Phase 1/2 interventional study of BYL719 as film-coated (FC) whole tablets and BYL719 as dispersible tablets (DT) in Recurrent Head and Neck Squamous Cell Carcinoma and Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Terminated at 29 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-29.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.
Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 13th largest by enrollment of the 84 interventional ones that give a count, is one of 4 that started in 2012, is one of 8 in phase 1/2, and was the 43rd registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:
NRG Oncology · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Sites in Spain
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 51 · Phase 3 18
First in 1999; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 179 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 46 across the 84 interventional studies. Of the 59 that completed or were terminated, 32 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 86 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 9 studies filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
4 of the studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04375384Wake Forest University Health SciencesCetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer | 2026-12 |
| NCT06978829Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityCetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC | 2027-03-31 |
| NCT04722523Memorial Sloan Kettering Cancer CenterA Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | 2027-06-20 |
| NCT06869473Gruppo Oncologico del Nord-OvestCetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. | 2027-08-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a multi-center, open-label, Phase Ib dose escalation /Phase II study in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) patients considered to be resistant, ineligible or intolerant to platinum-based chemotherapy. The Phase Ib included three arms. Three different methods of administration and two different BYL719 formulations were studied to determine the MTD and/or RP2D of BYL719 in combination with cetuximab:
Arm A - film-coated whole tablets were orally administered to patients who were able to swallow the tablets; Arm B - a drinkable suspension prepared from crushed film-coated tablets was administered orally to patients with swallowing dysfunction Arm C - a suspension from a dispersible tablet administered via G-tube, in patients with swallowing dysfunction. Arm C was used to investigate the pharmacokinetics (PK), compared to Arm A (film coated tablet), and safety of the dispersible tablet of the dispersible tablet formulation of BYL719.
The Phase II investigated the clinical efficacy of BYL719 and consisted of an open label, randomized Phase II part investigating BYL719 in combination with cetuximab compared to cetuximab alone in patients resistant or intolerant to platinum and naïve to cetuximab (Scheme 1: Arm 1 and Arm 2), and a non-randomized Phase II part Scheme 2: Arm 3. In addition, patients who experienced disease progression in Arm 2 (cetuximab) were allowed to switch to the combination regimen (cross-over, Arm 2B). The safety of the BYL719 in combination with cetuximab was also further characterized in Arms 1, 2B and 3.
Patients were treated until progression of disease), unacceptable toxicity, or withdrawal of informed consent, whichever occurred first (except for phase II Arm 2 had the opportunity to crossover to the combination treatment (Arm 2B). In the follow-up period all patients had to complete the safety follow-up assessments within 30 days after the last dose of the study treatment. Patients who did not have disease progression at the time of discontinuation of study treatment were radiologically followed for disease status until disease progression, initiation of subsequent anticancer therapies, or death, whichever occurred first. In addition, all patients enrolled in Phase II were followed for survival.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral film-coated tablets without swallowing dysfunction.
Drug: BYL719 as film-coated (FC) whole tablets · Biological: cetuximab
Cetuximab in patients naive to cetuximab (phase ll)
Biological: cetuximab
Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
Biological: cetuximab · Drug: BYL719 drink suspension
BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
Drug: BYL719 as film-coated (FC) whole tablets · Biological: cetuximab · Drug: BYL719 drink suspension
BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
Drug: BYL719 as film-coated (FC) whole tablets · Biological: cetuximab · Drug: BYL719 drink suspension
Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
Drug: BYL719 as dispersible tablets (DT) · Biological: cetuximab
patients received BYL719 at RP2D in combination with cetuximab.
Drug: BYL719 as film-coated (FC) whole tablets · Biological: cetuximab
Oral alpha-specific PI3K inhibitor
Also known as: NVP-BYL719, alpelisib
New formulation of the oral alpha-specific PI3K inhibitor
Also known as: NVP-BYL719
Recombinant chimeric monoclonal antibody driven against EGFR
Also known as: erbitux
Oral alpha-specific PI3K inhibitor
Also known as: NVP-BYL719
Phase Ib Arms A: Probability That Dose Limiting Toxicities (DLTs) Rate is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)
Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR \> 1) \< 10%, and the posterior median HR \< 0.7.
Time frame: until disease progression or intolerable toxicity (approximately 6 months)
Phase Ib Arm B: Probability That Distribution of Dose Limiting Toxicities (DLTs) is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)
Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm B (crushed film-coated tablets as an oral suspension with swallowing dysfunction). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR \> 1) \< 10%, and the posterior median HR \< 0.7.
Time frame: until disease progression or intolerable toxicity (approximately 6 months)
For Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 Days)
Estimation of Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets) and arm B (BYL719 administered as a drinkable suspension in patients with swallowing dysfunction). 6 months is an approximate timeframe.
Time frame: until disease progression or intolerable toxicity (approximately 6 months)
Phase II Arms 1 and 2: Progression Free Survival (PFS) as Per RECIST v1.1 by Central Radiology Review
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab. 6 months is an approximate timeframe.
Time frame: approximately 6 months
Phase II Arm 3: Progression Free Survival (PFS) as Per RECIST V1.1
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab in patients resistant to platinum-based therapy and cetuximab.
Time frame: approximately 6 months
Phase Ib: Area Under Curve (AUC) 0-24 for BYL719 by Treatment
Comparison of single-dose exposure of BYL719 dispersible tablet via G-tube in combination with cetuximab in RM HNSCC to that of Arm A (film-coated tables)
Time frame: 6 months
Phase II: Progression Free Survival (PFS) as Per RECIST v 1.1
Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab
Time frame: approximately 6 months
Phase Ib: Progression Free Survival (PFS) as Per RECIST v1.1
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C.
Time frame: approximately 6 months
Phase II: Randomized Best Overall Response as Per RECIST v1.1
Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Time frame: approximately 6 months
Phase II: Non-Randomized Best Overall Response as Per RECIST v1.1
Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Time frame: approximately 6 months
Phase II: Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arms 1 and 2.
Time frame: approximately 6 months
Phase II: Non-Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
Scheme 1 (arm 3): Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm 3 (non-randomized arm)
Time frame: approximately 6 months
Phase II: Randomized Overall Survival (OS) by Treatment
Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Time frame: approximately 1 year
Phase II: Non-Randomized Overall Survival (OS) by Treatment
Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Time frame: approximately 1 year
For Phase Ib: Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C CR=complete response PR=partial response
Time frame: approximately 6 months
Phase II, Scheme 1 (Arm 2B): Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
Phase II: Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab. Complete response (CR); Partial response (PR); Stable disease (SD)
Time frame: Approximately 6 months
Phase II, Scheme 2 (Arm 2B): Overall Survival (OS) for the Cross-over
Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab.
Time frame: approximately 1 year
Phase Ib: Primary Plasma Pharmacokinetic Parameters for BYL719 by Treatment
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
Time frame: 1 to 24 hours post dose (Day 1 Cycle 1)
Phase Ib: Cmax for BYL719 by Treatment
Non compartmental Cmax derived after single dose at Cycle 1 Day 1
Time frame: Day 1 Cycle 1
Phase Ib: Tmax for BYL719 by Treatment
Non compartmental Cmax derived after single dose at Cycle 1 Day 1
Time frame: Day 1 Cycle 1
Phase Ib: Plasma Pharmacokinetic Parameters for BYL719 After Continuous Dose Administration (Steady State)
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
Time frame: Day 1 Cycle 1
Phase Ib: Cmax for BYL719 After Continuous Dose Administration (Steady State)
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
Time frame: Day 1 Cycle 1
Phase Ib: Tmax for BYL719 After Continuous Dose Administration (Steady State)
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
Time frame: Day 1 Cycle 1
Phase Ib: Notable Abnormal Vital Signs by Treatment
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.
Time frame: approximately 6 months
Phase Ib: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.
Time frame: baseline, post baseline
For Phase II: Notable Abnormal Vital Signs by Treatment
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.
Time frame: approximately 6 months
For Phase II: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.
Time frame: baseline, post baseline during the entire study period (approximately 1 year)
Phase II: Progression Free Survival (PFS) Based on Investigator's Assessment With Treatment
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
Time frame: approximately 6 months
45 patients enrolled in Phase Ib, 106 cetuximab naïve patients in Phase II were randomized to either BYL719+cet (N=71) or cet monotherapy (N=35). Of the 35 patients, 16 crossed over to BYL719+cet combo treatment. 29 patients enrolled in the non-randomized combo treatment arm (cet resistant patients). All patients have completed the trial.
| Milestone | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab | Arm B - BYL719 + Cetuximab, Oral Suspension | Arm C - BYL719+Cetuximab, Dispersible Tablets | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | Arm 3 - BYL719+Cetuximab (Non-randomized) |
|---|---|---|---|---|---|---|---|
| Started | 16 | 5 | 18 | 6 | 71 | 35 | 29 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 16 | 5 | 18 | 6 | 71 | 35 | 29 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 | 0 | 0 | 2 | 1 | 1 |
| Withdrew: Disease progression | 6 | 3 | 10 | 1 | 41 | 12 | 15 |
| Withdrew: Death | 1 | 1 | 1 | 1 | 7 | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 | 2 | 0 | 6 | 0 | 1 |
| Withdrew: Adverse event | 5 | 1 | 5 | 4 | 15 | 3 | 9 |
| Withdrew: Subject/guardian decision | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Cross-over patients to combo treatment | 0 | 0 | 0 | 0 | 0 | 16 | 0 |
Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR \> 1) \< 10%, and the posterior median HR \< 0.7.
| Probability of DLT rate | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab |
|---|---|---|
| Posterior probabilities that Pr(DLT) in 0-0.16 | 0.764 | 0.086 |
| Posterior probabilities that Pr (DLT) in 0.16-0.35 | 0.222 | 0.376 |
| Posterior probabilities that Pr (DLT) in 0.35-1 | 0.015 | 0.538 |
Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm B (crushed film-coated tablets as an oral suspension with swallowing dysfunction). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR \> 1) \< 10%, and the posterior median HR \< 0.7.
| Probability of DLT rate | Arm B- 300mg BYL719+Cetuximab |
|---|---|
| Posterior probabilities that Pr(DLT) in 0-0.16 | 0.267 |
| Posterior probabilities that Pr (DLT) in 0.16-0.35 | 0.664 |
| Posterior probabilities that Pr (DLT) in 0.35-1 | 0.069 |
Estimation of Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets) and arm B (BYL719 administered as a drinkable suspension in patients with swallowing dysfunction). 6 months is an approximate timeframe.
| Participants | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab | Arm B - BYL719 + Cetuximab, Oral Suspension | Arm C - BYL719+Cetuximab, Dispersible Tablets | All Patients |
|---|---|---|---|---|---|
| For Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 Days) | 1 | 2 | 4 | 2 | 9 |
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab. 6 months is an approximate timeframe.
| participants | BYL719+ Cetuximab (Randomized) | Monotherapy Cetuximab (Randomized) |
|---|---|---|
| Number of PFS events | 46 (0.643 to 1.529) | 27 |
| Progression | 33 | 25 |
| Number of censored | 25 | 8 |
| Death | 13 | 2 |
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab in patients resistant to platinum-based therapy and cetuximab.
| months | BYL719+ Cetuximab (Non-randomized) |
|---|---|
| Phase II Arm 3: Progression Free Survival (PFS) as Per RECIST V1.1 | 3.896 (2.868 to 5.241) |
Comparison of single-dose exposure of BYL719 dispersible tablet via G-tube in combination with cetuximab in RM HNSCC to that of Arm A (film-coated tables)
| hr*ng/mL | Arm A - 300mg BYL719+Cetuximab | Arm C: BYL719+Cetixumab, Dispersible Tablets | Arm A: 400mg BYL719 + Cetuximab | Arm B: 300mg BYL719 + Cetuximab |
|---|---|---|---|---|
| AUCinf | 22600 (16600 to 48500) | 24100 (9290 to 33200) | 27800 (17200 to 60100) | 27300 (15700 to 47400) |
| AUC0_24 | 18800 (5590 to 43400) | 19400 (7580 to 32100) | 26300 (16000 to 56100) | 25600 (14600 to 42100) |
| AUClast | 19200 (5830 to 42700) | 22100 (4390 to 31800) | 26200 (15800 to 55600) | 25000 (14400 to 41900) |
Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab
| Participants | Arm 2B - BYL719+Cetuximab |
|---|---|
| Number of PFS | 12 |
| Progression | 9 |
| Death | 3 |
| Number of Censored | 4 |
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C.
| Participants | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab | Arm B - BYL719 + Cetuximab, Oral Suspension | Arm C - BYL719+Cetuximab, Dispersible Tablets |
|---|---|---|---|---|
| PFS event (Progression) | 5 | 2 | 10 | 2 |
| PFS event (Death) | 2 | 2 | 1 | 1 |
| Number of Censored | 9 | 1 | 7 | 3 |
Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
| Participants | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | All Patients |
|---|---|---|---|
| Complete Response | 1 | 0 | 1 |
| Partial Response | 6 | 2 | 8 |
| Stable Disease | 24 | 8 | 32 |
| Progressive Disease | 17 | 12 | 29 |
| Non-CR/Non-PD (NCRNPD) | 6 | 10 | 16 |
| Unknown | 17 | 3 | 20 |
Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
| Participants | Arm 3 - BYL719+Cetuximab |
|---|---|
| Complete Response (CR) | 1 |
| Partial Response (PR) | 2 |
| Stable Disease (SD) | 8 |
| Progressive Disease (PD) | 5 |
| Non-CR/Non-PD (NCRNPD) | 6 |
| Unknown | 7 |
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arms 1 and 2.
| Percentages | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | All Patients (Phase II) |
|---|---|---|---|
| Overall response rate (ORR) (CR or PR) | 9.9 (4.1 to 19.3) | 5.7 (0.7 to 19.2) | 8.5 (4.0 to 15.5) |
| Disease control rate 1 (DCR 1) (CR or PR or SD) | 43.7 (31.9 to 56.0) | 28.6 (14.6 to 46.3) | 38.7 (29.4 to 48.6) |
| DCR 2 (CR or PR or SD or Non-CR/Non-PD) | 52.1 (39.9 to 64.1) | 57.1 (39.4 to 73.7) | 53.8 (43.8 to 63.5) |
Scheme 1 (arm 3): Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm 3 (non-randomized arm)
| Percentages | Arm 3 - BYL719+Cetuximab |
|---|---|
| Overall response rate (ORR) (CR or PR) | 10.3 (2.2 to 27.4) |
| Disease control rate 1 (DCR 1) (CR or PR or SD) | 37.9 (20.7 to 57.7) |
| DCR 2 (CR or PR or SD or Non-CR/Non-PD) | 58.6 (38.9 to 76.5) |
Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
| Patients | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) |
|---|---|---|
| Number of deaths | 51 | 26 |
| Number of censored | 20 | 9 |
Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
| Patients | Arm 3 - BYL719+Cetuximab |
|---|---|
| Number of deaths | 13 |
| Number of censored | 10 |
Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C CR=complete response PR=partial response
| Percentages | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab | Arm B - BYL719 + Cetuximab, Oral Suspension | Arm C - BYL719+Cetuximab, Dispersible Tablets | All Patients |
|---|---|---|---|---|---|
| ORR (CR) or PR) | 25.5 (7.3 to 52.4) | 0.0 (0.0 to 52.2) | 0.0 (0.0 to 18.5) | 0.0 (0.0 to 45.9) | 8.9 (2.5 to 21.2) |
| DCR (CR or PR or Stable Disease or non-CR/Non-PD) | 75.0 (47.6 to 92.7) | 20.0 (0.5 to 71.6) | 50.0 (26.0 to 74.0) | 16.7 (0.4 to 64.1) | 51.1 (35.8 to 66.3) |
Phase II: Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab. Complete response (CR); Partial response (PR); Stable disease (SD)
| Rate | Arm 2B - BYL719+Cetuximab |
|---|---|
| Overall Response (ORR) - CR or PR | 0 (NA to NA) |
| Disease Control Rate (DCR) - CR, PR, or SD | 25.0 (7.27 to 52.38) |
Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab.
| Days | Arm 2B - BYL719+Cetuximab |
|---|---|
| Phase II, Scheme 2 (Arm 2B): Overall Survival (OS) for the Cross-over | 96.0 (87.0 to 148.0) |
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
| hr*ng/mL | Arm A - 300mg BYL719+Cetuximab | Arm B: BYL719 + Cetuximab, Oral Suspension | Arm C: BYL719+Cetixumab, Dispersible Tablets | Arm A: 400mg BYL719 + Cetuximab |
|---|---|---|---|---|
| AUCinf | 22600 (16600 to 48500) | 27300 (15700 to 47400) | 24100 (9290 to 33200) | 27800 (17200 to 60100) |
| AUC0_24 | 18800 (5590 to 43400) | 25600 (14600 to 42100) | 19400 (7580 to 32100) | 26300 (16000 to 56100) |
| AUClast | 19200 (5830 to 42700) | 2370 (1330 to 3710) | 22100 (4390 to 31800) | 26200 (15800 to 55600) |
Non compartmental Cmax derived after single dose at Cycle 1 Day 1
| ng/mL | Arm A - 300mg BYL719+Cetuximab | Arm B: BYL719 + Cetuximab, Oral Suspension | Arm C: BYL719+Cetixumab, Dispersible Tablets | Arm A: 400mg BYL719 + Cetuximab |
|---|---|---|---|---|
| Phase Ib: Cmax for BYL719 by Treatment | 2130 (303 to 4280) | 2370 (1330 to 3710) | 2010 (682 to 2980) | 2520 (1800 to 6240) |
Non compartmental Cmax derived after single dose at Cycle 1 Day 1
| hr | Arm A - 300mg BYL719+Cetuximab | Arm B: BYL719 + Cetuximab, Oral Suspension | Arm C: BYL719+Cetixumab, Dispersible Tablets | Arm A: 400mg BYL719 + Cetuximab |
|---|---|---|---|---|
| Phase Ib: Tmax for BYL719 by Treatment | 2.02 (1 to 24.8) | 2.97 (1 to 5.87) | 3 (0.767 to 6) | 2.23 (1.58 to 3.02) |
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
| hr*ng/mL | Arm A - 300mg BYL719+Cetuximab | Arm B: BYL719 + Cetuximab, Oral Suspension | Arm C: BYL719+Cetixumab, Dispersible Tablets |
|---|---|---|---|
| AUC (0-24) | 24600 (17900 to 44400) | 28500 (12700 to 53900) | 30500 (30500 to 30500) |
| AUClast | 24500 (18000 to 76100) | 2370 (1330 to 3710) | 22100 (4390 to 31800) |
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
| ng/mL | Arm A - 300mg BYL719+Cetuximab | Arm B: BYL719 + Cetuximab, Oral Suspension | Arm C: BYL719+Cetixumab, Dispersible Tablets |
|---|---|---|---|
| Phase Ib: Cmax for BYL719 After Continuous Dose Administration (Steady State) | 2200 (1710 to 6520) | 2820 (373 to 4710) | 2750 (2750 to 2750) |
Non compartmental PK parameters derived after single dose at Cycle 1 Day 1
| hr | Arm A - 300mg BYL719+Cetuximab | Arm B: BYL719 + Cetuximab, Oral Suspension | Arm C: BYL719+Cetixumab, Dispersible Tablets |
|---|---|---|---|
| Phase Ib: Tmax for BYL719 After Continuous Dose Administration (Steady State) | 3.15 (1.5 to 7.13) | 3.15 (1.03 to 8) | 1 (1 to 1) |
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.
| Participants | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab | Arm B - BYL719 + Cetuximab, Oral Suspension | Arm C - BYL719+Cetuximab, Dispersible Tablets |
|---|---|---|---|---|
| Sitting Pulse rate (bpm): High only | 0 | 0 | 4 | 4 |
| Sitting Pulse rate (bpm): Low only | 0 | 0 | 0 | 0 |
| Sitting Pulse rate (bpm): High and low | 0 | 0 | 0 | 0 |
| Sitting systolic B.P. (mmHg): High only | 1 | 0 | 1 | 0 |
| Sitting systolic B.P. (mmHg): Low only | 1 | 0 | 0 | 1 |
| Sitting systolic B.P. (mmHg): High and low | 0 | 0 | 1 | 0 |
| Sitting diastolic B.P. (mmHg): High only | 0 | 0 | 1 | 0 |
| Sitting diastolic B.P. (mmHg): Low only | 1 | 0 | 2 | 0 |
| Sitting diastolic B.P. (mmHg): High and low | 0 | 0 | 0 | 0 |
| Body Temperature (Celsius): High only | 0 | 0 | 0 | 1 |
| Body Temperature (Celsius): Low only | 0 | 0 | 0 | 0 |
| Body Temperature (Celsius): High and low | 0 | 0 | 0 | 0 |
| Weight (kg): High only | 0 | 0 | 0 | 0 |
| Weight (kg): Low only | 7 | 1 | 3 | 3 |
| Weight (kg): High and low | 0 | 0 | 0 | 0 |
| Respiratory Rate (bpm): High only | 0 | 0 | 2 | 1 |
| Respiratory Rate (bpm): Low only | 0 | 0 | 0 | 0 |
| Respiratory Rate (bpm): High and low | 0 | 0 | 0 | 0 |
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.
| Participants | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab | Arm B - BYL719 + Cetuximab, Oral Suspension | Arm C - BYL719+Cetuximab, Dispersible Tablets |
|---|---|---|---|---|
| QTcF (msec): Increase from baseline > 30 | 9 | 4 | 10 | 1 |
| QTcF (msec): Increase from baseline > 60 | 2 | 0 | 1 | 0 |
| QTcB (msec): Increase from baseline > 30 | 11 | 4 | 12 | 1 |
| QTcB (msec): Increase from baseline > 60 | 1 | 0 | 1 | 1 |
| QT (msec): Increase from baseline > 30 | 1 | 4 | 10 | 1 |
| QT (msec): Increase from baseline > 60 | 4 | 0 | 3 | 0 |
| VR (bpm): RR decrease > 25% & to a VR > 100 | 0 | 1 | 1 | 1 |
| VR (bpm): RR decrease > 25% & to a VR < 50 | 0 | 0 | 0 | 0 |
| PR (msec): increase > 25% & to a VR > 200 | 0 | 0 | 0 | 0 |
| QRS (msec): increase > 25% & to a VR > 110 | 0 | 0 | 0 | 0 |
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.
| Participants | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | Arm 2B - BYL719+Cetuximab |
|---|---|---|---|
| Sitting Pulse rate (bpm): High only | 4 | 3 | 5 |
| Sitting Pulse rate (bpm): Low only | 1 | 0 | 1 |
| Sitting Pulse rate (bpm): High and low | 0 | 0 | 0 |
| Sitting systolic B.P. (mmHg): High only | 0 | 1 | 0 |
| Sitting systolic B.P. (mmHg): Low only | 11 | 3 | 1 |
| Sitting systolic B.P. (mmHg): High and low | 1 | 0 | 0 |
| Sitting diastolic B.P. (mmHg): High only | 1 | 2 | 0 |
| Sitting diastolic B.P. (mmHg): Low only | 4 | 3 | 2 |
| Sitting diastolic B.P. (mmHg): High and low | 1 | 0 | 0 |
| Body Temperature (Celsius): High only | 1 | 0 | 0 |
| Body Temperature (Celsius): Low only | 3 | 1 | 2 |
| Body Temperature (Celsius): High and low | 0 | 0 | 0 |
| Weight (kg): High only | 1 | 4 | 0 |
| Weight (kg): Low only | 31 | 3 | 9 |
| Weight (kg): High and low | 0 | 0 | 0 |
| Respiratory Rate (bpm): High only | 2 | 0 | 1 |
| Respiratory Rate (bpm): Low only | 2 | 1 | 4 |
| Respiratory Rate (bpm): High and low | 0 | 0 | 0 |
Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.
| Participants | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | Arm 2B - BYL719+Cetuximab |
|---|---|---|---|
| QTcF (msec): Increase from baseline > 30 | 35 | 4 | 15 |
| QTcF (msec): Increase from baseline > 60 | 6 | 1 | 2 |
| QTcB (msec): Increase from baseline > 30 | 40 | 12 | 15 |
| QTcB (msec): Increase from baseline > 60 | 7 | 0 | 2 |
| QT (msec): Increase from baseline > 30 | 43 | 13 | 23 |
| QT (msec): Increase from baseline > 60 | 17 | 2 | 5 |
| VR (bpm): RR decrease > 25% & to a VR > 100 | 9 | 4 | 3 |
| VR (bpm): RR decrease > 25% & to a VR < 50 | 1 | 0 | 0 |
| PR (msec): increase > 25% & to a VR > 200 | 0 | 0 | 0 |
| QRS (msec): increase > 25% & to a VR > 110 | 0 | 0 | 1 |
Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab
| Days | BYL719+ Cetuximab (Randomized) | Monotherapy Cetuximab (Randomized) | BYL719=Cetuximab (Non-randomized) |
|---|---|---|---|
| Phase II: Progression Free Survival (PFS) Based on Investigator's Assessment With Treatment | 94.0 (58.0 to 135.0) | 85.0 (49.0 to 127.0) | 117.0 (50.0 to 184.0) |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse Events reported in this record are from date of First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A - 300mg BYL719+Cetuximab | — | 9/15 (60%) | 15/15 (100%) |
| Arm A: 400 mg BYL719 + Cetuximab | — | 4/5 (80%) | 5/5 (100%) |
| Arm B - BYL719 + Cetuximab Oral Suspension | — | 12/18 (66.7%) | 18/18 (100%) |
| Arm C - BYL719+Cetuximab Dispersible Tablets | — | 4/6 (66.7%) | 6/6 (100%) |
| Arm 1 - BYL719+Cetuximab (Randomized) | — | 40/69 (58%) | 69/69 (100%) |
| Arm 2 - Monotherapy Cetuximab (Randomized) | — | 15/35 (42.9%) | 35/35 (100%) |
| Arm 3 - BYL719+Cetuximab (Non-randomized) | — | 15/29 (51.7%) | 29/29 (100%) |
| All Patients | — | 99/178 (55.6%) | 177/178 (99.4%) |
| Event | Arm A - 300mg BYL719+Cetuximab | Arm A: 400 mg BYL719 + Cetuximab | Arm B - BYL719 + Cetuximab Oral Suspension | Arm C - BYL719+Cetuximab Dispersible Tablets | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | Arm 3 - BYL719+Cetuximab (Non-randomized) | All Patients |
|---|---|---|---|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 1/15 | 0/5 | 0/18 | 2/6 | 7/69 | 0/35 | 5/29 | 15/178 |
| PneumoniaInfections and infestations | 2/15 | 0/5 | 4/18 | 1/6 | 8/69 | 1/35 | 4/29 | 20/178 |
| Myocardial ischaemiaCardiac disorders | 0/15 | 1/5 | 0/18 | 0/6 | 0/69 | 0/35 | 0/29 | 1/178 |
| Oesophageal ulcerGastrointestinal disorders | 0/15 | 1/5 | 0/18 | 0/6 | 0/69 | 0/35 | 0/29 | 1/178 |
| Tumour lysis syndromeMetabolism and nutrition disorders | 0/15 | 1/5 | 0/18 | 0/6 | 0/69 | 0/35 | 0/29 | 1/178 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/15 | 1/5 | 0/18 | 0/6 | 3/69 | 0/35 | 0/29 | 4/178 |
| Device dislocationProduct Issues | 0/15 | 1/5 | 0/18 | 0/6 | 0/69 | 0/35 | 0/29 | 1/178 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/15 | 1/5 | 0/18 | 0/6 | 3/69 | 1/35 | 1/29 | 6/178 |
| Atrial fibrillationCardiac disorders | 0/15 | 0/5 | 0/18 | 1/6 | 1/69 | 0/35 | 0/29 | 2/178 |
| PyrexiaGeneral disorders | 1/15 | 0/5 | 1/18 | 1/6 | 4/69 | 1/35 | 0/29 | 8/178 |
| Event | Arm A - 300mg BYL719+Cetuximab | Arm A: 400 mg BYL719 + Cetuximab | Arm B - BYL719 + Cetuximab Oral Suspension | Arm C - BYL719+Cetuximab Dispersible Tablets | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | Arm 3 - BYL719+Cetuximab (Non-randomized) | All Patients |
|---|---|---|---|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 8/15 | 2/5 | 10/18 | 5/6 | 42/69 | 5/35 | 16/29 | 88/178 |
| DiarrhoeaGastrointestinal disorders | 7/15 | 2/5 | 10/18 | 2/6 | 29/69 | 5/35 | 13/29 | 68/178 |
| HypomagnesaemiaMetabolism and nutrition disorders | 8/15 | 2/5 | 6/18 | 1/6 | 18/69 | 8/35 | 12/29 | 55/178 |
| ConstipationGastrointestinal disorders | 2/15 | 0/5 | 4/18 | 3/6 | 9/69 | 7/35 | 5/29 | 30/178 |
| Weight decreasedInvestigations | 6/15 | 2/5 | 6/18 | 3/6 | 27/69 | 7/35 | 11/29 | 62/178 |
| DehydrationMetabolism and nutrition disorders | 0/15 | 1/5 | 0/18 | 3/6 | 5/69 | 1/35 | 3/29 | 13/178 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/15 | 1/5 | 1/18 | 3/6 | 4/69 | 2/35 | 2/29 | 13/178 |
| FatigueGeneral disorders | 5/15 | 2/5 | 5/18 | 0/6 | 22/69 | 8/35 | 14/29 | 56/178 |
| StomatitisGastrointestinal disorders | 7/15 | 2/5 | 8/18 | 1/6 | 31/69 | 6/35 | 12/29 | 67/178 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 7/15 | 2/5 | 4/18 | 0/6 | 21/69 | 8/35 | 5/29 | 47/178 |
Full Analysis Set (FAS) consisted of all patients who received at least one dose of either BYL719 or Cetuximab in Phase Ib and Phase II Arm 3, and all randomized patients in Phase II Scheme 1, Arm 1 and Arm 2.
| Age, Continuous(years) | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab | Arm B - BYL719 + Cetuximab, Oral Suspension | Arm C - BYL719+Cetuximab, Dispersible Tablets | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | Arm 3 - BYL719+Cetuximab (Non-randomized) | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 52.8 ± 13.40 | 62.6 ± 7.99 | 56.7 ± 10.20 | 60.5 ± 14.10 | 57.2 ± 9.66 | 57.1 ± 10.37 | 56.9 ± 8.25 | 57.0 ± 10.16 |
| Sex: Female, Male(Participants) | Arm A - 300mg BYL719+Cetuximab | Arm A - 400mg BYL719+Cetuximab | Arm B - BYL719 + Cetuximab, Oral Suspension | Arm C - BYL719+Cetuximab, Dispersible Tablets | Arm 1 - BYL719+Cetuximab (Randomized) | Arm 2 - Monotherapy Cetuximab (Randomized) | Arm 3 - BYL719+Cetuximab (Non-randomized) | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 7 | 1 | 4 | 2 | 16 | 4 | 10 | 44 |
| Male | 9 | 4 | 14 | 4 | 55 | 31 | 19 | 136 |
Plan to share: No
Ran from Nov 2012 to primary completion in Sep 2016, 46 months.
Results were first posted in May 2018, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alpelisib · Cetuximab
Squamous Cell Carcinoma of Head and Neck →